The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | IASC WCLC 2021: CX-2029 and AMG 757 for lung cancer
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, gives an outline of the data she will be presenting at WCLC 2021. Dr Johnson will give an update on the Phase I/II PROCLAIM-CX-2029 trial (NCT03543813) investigating the CD71-directed antibody-drug conjugate CX-2029 in squamous cell lung cancer, gastric cancer and head and neck cancer. She will also share some new data from a trial of AMG 757, a DLL3-targeted bispecific T-cell engager (BiTE), in adults with small cell lung cancer (NCT03319940). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
